---
title: "Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer: Storage and supply questions"
description: "Storage and supply questions on Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: How supplied and Storage. Questions: How is DATROWAY supplied? How should DATROWAY be stored? 2 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/storage-and-supply"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer: Storage and supply questions

Manufacturer: Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP  
Prescribing information: [Datroway](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Datroway&inline=true)

## How supplied

<a id="datroway-supply-storage"></a>

### How is DATROWAY supplied?

> “Strength: 100 mg per vial
> Dosage form: White to yellowish white, lyophilized powder in a single-dose vial for reconstitution and further dilution”

Source: [DATROWAY: Dosing & Administration, captured 2026-11-08](https://datrowayhcp.com/dosing-administration#:~:text=Strength%3A%20100%20mg%20per%20vial,for%20reconstitution%20and%20further%20dilution)

## Storage

<a id="datroway-storage"></a>

### How should DATROWAY be stored?

> “Store vials in a refrigerator at 2ºC to 8ºC (36ºF to 46ºF) in the original carton to protect from light until time of 
> reconstitution. Do not freeze. Do not shake the reconstituted or diluted solution [see Dosage and Administration (2.5)]. 
>
> DATROWAY (datopotamab deruxtecan-dlnk) is a hazardous drug. Follow applicable special handling and disposal 
> procedures.<sup>1</sup>”

Source: [DATROWAY: Prescribing information, page 23, captured 2026-11-08](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Datroway&inline=true#page=23)

## Related pages
- [Medical information: Datroway (datopotamab deruxtecan-dlnk): HR-positive HER2-negative breast cancer](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/access-and-coverage)
